A systematic literature review according to Preferred Reporting Items for Systematic Review (PRISMA) standard was conducted to investigate the influence of PDMP’s strength in combating the incidence of drug abuse and also to review the weaknesses of PDMP that prohibit its implementation. Although the establishment of PDMP in the US was since 2003, evidence of the impact of PDMP’s strength and weakness towards its implementation is still scarce. Prescription Drug Monitoring Program (PDMP) is an electronic database that tracks the prescriptions of controlled drugs with its aims to combat the incidence of drug abuse. Our study found that health care providers underutilize prescription monitoring program data and that many barriers exist to prescription monitoring program data use. Common barriers to prescription monitoring program data use included time constraints and administrative burdens, low perceived value of prescription monitoring program data, and problems with prescription monitoring program system usability. The pooled proportion of health care providers who had ever used prescription monitoring program data was 0.57 (95% confidence interval: 0.48–0.66). Of these, 46 reported on prescription monitoring program use and 32 reported on barriers. We pooled the proportion of health care providers who had ever used prescription monitoring program data by using random effects models, and we used meta-summary methodology to identify prescription monitoring program use barriers.įifty-three studies were included in our review, all from the United States. We synthesized outcomes related to prescription monitoring program data use (i.e., ever used, frequency of use). We identified relevant quantitative and qualitative studies. We included full-published peer-reviewed reports of study data, as well as theses and dissertations. We performed a systematic review using a standard systematic review method with meta-analysis and qualitative meta-summary. To synthesize the literature on the proportion of health care providers who access and use prescription monitoring program data in their practice, as well as associated barriers to the use of such data.
0 kommentar(er)
